Seabourn announced its 2029 Summer Ocean Voyages featuring 166 sailings to over 180 destinations across the Mediterranean, Northern Europe, Alaska, Canada, and New England. Highlights include a return to Egypt after five years with overnight stays in Alexandria, a new Gulf of Bothnia itinerary exploring Sweden and Finland, and maiden calls in Northern Europe. The collection offers extended stays and boutique ports for deeper exploration, with Alaska voyages led by an expert Expedition Team. These voyages provide luxury experiences combining iconic and less-traveled destinations with personalized service.
Seabourn's 2029 Ocean Voyages are detailed here as context for readers. For those tracking Consumer Cyclical-sector US stocks on Pluang, 23 of 134 stocks rose while 111 fell. Notable movers include Macy's Inc (M) at USD 21.91 with a 3.65% decline and 83% sell order activity, MINISO Group Holding Ltd (MNSO) at USD 10.28 up 3.63% but with 100% sell orders, and Lennar Corporation (LEN) at USD 72.22 down 3.60% with 77% buy orders. Data is as of Oct 14, 2026 21:41 WIB.
Jefferies has maintained a Buy rating on Big Yellow Group despite recent stock declines, citing the company's strong fundamentals including freehold properties and solid cash flows. Activist investor Ancora, holding over 4% of shares, is pushing Big ...
Fastenal reported strong Q3 2026 earnings, beating analyst expectations with EPS of $0.35 and revenue of $2.46 billion. The company saw a 20% rise in net income to $401.6 million and a 15.5% increase in revenue driven by robust manufacturing demand, ...
Remittix announced the public launch of its RTX token on November 24, 2026, marking the end of its presale phase which raised over $32 million from 40,000 participants. The project is testing its PayFi platform, which enables crypto-to-fiat and fiat-...
The global microbiology testing market is projected to grow rapidly at a compound annual growth rate (CAGR) of approximately 9% from 2026 to 2034, reaching a market size of $13.7 billion by 2034. This growth is driven by the rising prevalence of infe...
H.C. Wainwright raised its price target for Alector from $5.00 to $8.00, maintaining a Buy rating due to progress in its neurodegenerative disease pipeline. Alector develops treatments for Alzheimer's and Parkinson's using its Brain Carrier platform ...
